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Abstract
Hormone-receptor positive HER2-negative breast cancer constitutes about 2/3 of breast 
cancer. Hormonal therapy such as tamoxifen and aromatase inhibitors has been the main 
stay of treatment which gives favorable quality of life compared with traditional chemo-
therapy. However, the efficacy of subsequent hormonal therapy declines rapidly after 
the patients develops resistance to first line hormonal therapy. In recent years, there have 
been many breakthrough in the treatment of this cancer. A number of targeted agents 
including CDK4/6 inhibitor and mTOR inhibitor are now part of standard treatment 
paradigm to help prolong the use of hormonal therapy. New understanding in potential 
biomarker of resistance such as ESR1 mutation or PIK3CA mutation has also empowered 
us to develops personalized approach in treatment. This article will explain the treatment 
logistic for this cancer, current knowledge in hormonal resistance, findings of key clinical 
trials that define the current treatment paradigm, efficacy and major side effect precau-
tion of the targeted agents, and the unmet needs.
Keywords: metastatic breast cancer, hormone-receptor positive, CDK4/6 inhibitor, 
SERD, mTOR inhibitor
1. Introduction
Breast cancer is a common cancer in female with a high chance of recurrence even after curative 
treatment. The goal for treatment in metastatic disease is life prolongation and preservation of 
quality of life. Breast cancer is defined by the overexpression of hormone receptor (HR), either 
estrogen and/or progesterone receptors, and human epidermal growth factor receptor 2 (HER2) 
receptor. HR-positive HER2-negative (HR+ve/HER2−ve) breast cancer accounts for 70% of breast 
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cancer [1]. For patients with HR+ve/HER2−ve metastatic breast cancer (MBC), the choice between 
chemotherapy versus endocrine therapy depends on the disease load especially the presence 
of visceral crisis – patients with impending visceral crisis should be treated with systemic che-
motherapy, whereas patients with stable condition should be given endocrine therapy. As hor-
monal stimulation is known to be the underlying driving force and these tumors tend to be 
slow growing, endocrine therapy is considered the mainstay of treatment for most patients.
The first endocrine therapy described for treatment of MBC was tamoxifen which dated back in 
year 1971 [2]. It is a selective estrogen receptor modulator (SERMs) that binds competitively to 
estrogen receptors, and can have both antagonistic and agonistic effect depending on the tissue 
of action. Nowadays tamoxifen and raloxifen are the most commonly used SERMs clinically. 
SERMs can be used in both pre- and post-menopausal women. These drugs are well tolerated 
and have favorable toxicity profile. The use of aromatase inhibitor (AI) was started in early 
2000s for post-menopausal women. AI blocks the action of peripheral aromatase, preventing 
conversion of androgens to estrogen. Letrozole and anastrozole are non-steroidal reversible 
AIs, whereas exemestane is a steroidal irreversible AI. The initial evidence to support the use 
of AI was by the TARGET trial, which showed equivalent efficacy of anastrozole and tamoxi-
fen in the first line treatment of HR-positive MBC but with lower incidence of side effects such 
as thromboembolic events and vaginal bleeding [3]. Subsequently letrozole was demonstrated 
to have superior time to progression (9.4 versus 6.0 months, p < 0.0001), improved objective 
response rate (ORR) (32 versus 21%, p −0.0002) and a trend toward longer overall survival 
(OS) (34 versus 30 months) compared with tamoxifen [4]. The third class of endocrine therapy 
is selective estrogen-receptor degrader (SERD), and fulvestrant is the only SERD approved 
by the U.S. Food and Drug Administration (FDA) so far. In the CONFIRM trial, it has been 
defined that fulvestrant should be given at a higher dose of 500 mg instead of 250 mg for its 
better benefit in overall survival [5]. In the recently published phase 3 FALCON trial in which 
endocrine therapy-naïve patients were randomized to receive fulvestrant 500 mg monthly or 
anastrozole 1 mg daily [6]. The progression-free survival (PFS) in the fulvestrant group was 
16.6 months compared with that of 13.8 months in the anastrozole group. The p-value was at 
a borderline of 0.0486 and the overall survival data is not available yet. As such, both AI and 
fulvestrant are acceptable option for initial treatment of HR+ve/HER2−ve MBC, yet the use of 
fulvestrant is often limited by the need for monthly intramuscular injection and its high cost.
Traditional endocrine therapy at the frontline setting achieves an overall response rate in the 
range of 25–45% and median PFS around 8–10 months [3, 4, 7]. Second line endocrine therapy 
often yields unfavorable response. With improving understanding in this disease, more and 
more evidence suggests that combining endocrine therapy with targeted therapy could over-
come endocrine resistance and significantly prolong the time on endocrine therapy, delaying 
the needs for chemotherapy. This chapter will discuss the latest development in the targeted 
therapy for HR+ve/HER2−ve MBC and the future direction.
2. Endocrine resistance
Endocrine resistance is a major obstacle for treatment of HR+ve/HER2−ve MBC. Multiple 
mechanisms have been implicated. Based on these knowledge we now have a number of 
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targeted therapy that can help overcome this problem. The more clinically relevant mecha-
nisms are discussed as below.
2.1. Dysregulation of cell cycle checkpoints
In mammalian cells, cell cycle progression is determined by the checkpoint regular retinoblas-
toma protein (Rb), which itself is controlled by a number of cyclin-dependent kinases (CDK) 
[8]. In quiescent state, Rb in its hypo-phosphorylated state suppresses the cell cycle progression 
from G1 phase into S (synthesis) phase. In proliferative state, CDK subtypes 4 and 6 complexes 
with cyclin D1, D2, or D3, triggering Rb phosphorylation [9]. Hyperphosphorylation of Rb 
leads to increased activity of the E2F family of transcription factors and promotes cell cycle 
progression. Cyclin D1 amplification is common in HR-positive breast cancer. Cyclin D1 is 
encoded by CCDN1. CCND1 and cyclin D1 have been found to be amplified in 15–20 and 
28–58% of luminal breast cancer respectively [10, 11]. Preclinical research suggested dysregu-
lated cell cycle checkpoint regulation could lead to abnormal cell cycle progression and loss of 
endocrine responsiveness. Treatment of antiestrogen in breast cancer cells was associated with 
suppressed cyclin D1 expression, and emergence of endocrine resistance was accompanied by 
persistent cyclin D1 expression and Rb phosphorylation [12, 13]. Subsequent in vitro study fur-
ther demonstrated that in breast cancer cell lines, CDK4/6 inhibitor palbociclib had preferential 
activity in reversing treatment resistance in luminal cells [14]. A number of CDK4/6 inhibitors 
have been tested clinically, and have become standard treatment of HR+ve/HER2−ve MBC.
2.2. Crosstalk growth factor receptor and PI3K/AKT/mTOR pathway
Phosphatidylinositol-3-kinasd (PI3K)-Akt-mammalian target of rapamycin (mTOR) pathway 
is an important signal transduction system on which many growth factor receptors pathways 
converge. Crosstalk between the PI3K/Akt/mTOR pathway and growth factor receptors such 
as EGFR, HER2, HER2, FGFR1, and IGF1R have been described in endocrine resistance [15–18].
Abnormal activation of the PI3K pathway could result in factitious cell proliferation. The 
PI3K complex is composed of a regulatory subunit and a catalytic subunit p110. P110 has four 
isoforms – α, β, γ, and δ. PIK3CA mutation is found in up to 40% of breast cancer and is likely 
to be present in early cancer development [19, 20]. Abnormal PK3K signaling was found in 
up to 70% of breast cancers [21]. Besides PIK3CA mutation, hyperactivation of this pathway 
can result from aberration other PI3K subunits, mutation or phosphorylation of effectors Akt, 
loss of inhibitory signal from PTEN or INPPR4B, leading to activation of downstream effector 
mTOR protein. As hyperactivation of PI3K pathway could promote estrogen-independent ER 
transcriptional activation, inhibition of PI3K or its downstream effectors is an attractive target 
to overcome endocrine resistance [21, 22].
2.3. Changes in the estrogen receptor (ER) and HER2 status
Loss of HR expression, although uncommon, has been reported in hormone-resistant breast 
cancer. Study of paired primary and metastatic HR-positive breast cancer found a positive-to-
negative change in HR status in 10% of metastatic breast tumor [23]. In the P024 neoadjuvant 
endocrine therapy trial that recruited 228 post-menopausal women with HR-positive stage 
2 or 3 breast cancer, those who lost ER status after AI treatment had worse recurrence-free 
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survival compared with those who had no change in ER status (HR of relapse = 2.4, p = 0.03) 
[24]. Another study of paired sample analysis of primary cancer and liver metastases post-
treatment showed ER status and HER2 status change in 30% and 10% of patients [25]. How 
these changes in receptor status affect management and outcome is not well understood.
2.4. Molecular changes secondary to the use of aromatase inhibitor
Molecular changes in the target receptors after treatment causing treatment failure is a well-
known phenomenon in many malignancies. For HR-positive breast cancer, the target of 
interest is ESR1, which encodes for ERα. ESR1 mutation has not been detected in sequenc-
ing analysis of 390 treatment-naïve primary breast cancer tissues in the Cancer Genome 
Atlas project [11]. In another study, tissue of patients with hormone-resistance breast can-
cer were sequenced, and showed 14 or 80 these cases showed ESR1 mutations affecting the 
ligand-binding domain [26]. The mutations were the highly recurrent mutations encoding 
p.Tyr537Ser, p.Tyr537Asn and p.Asp538Gly alterations. p.Tyr537Ser and p.Asp538Gly play 
a role in hydrogen bonding of the mutant amino acid with Asp351 and favors the agonist 
conformation of the ER receptor. As a result the mutant ER becomes active in the absence 
of hormonal stimulation, and renders ER antagonists ineffective. The clinical significance of 
ESR1 mutation will be further discussed in Section 3.4.
3. New clinical therapy and emerging treatment
3.1. CDK4/6 inhibitor is now a new standard treatment
3.1.1. Palbociclib
Palbociclib is a first-in-class CDK4/6 inhibitor [27]. Based on the impressive PFS found in the 
phase 2 study PALOMA-1 [28], palbociclib was granted accelerated approval in 2015 by the 
Food and Drug Administration (FDA) for treatment of HR+ve/HER2−ve MBC in the first line 
setting.
3.1.1.1. Key results of phase 3 PALOMA studies
PALOMA-2, is a double-blind, placebo-controlled, randomized phase 3 study of palbociclib plus 
letrozole in women with HR+ve/HER2−ve MBC patients who had no prior treatment for advanced 
disease [29]. Patients were randomized to receive palbociclib plus letrozole or placebo plus letro-
zole. The primary end point was PFS. Secondary end points included OS, objective response 
rate (ORR), clinical benefit response (CBR) and safety. The study recruited 666 women within 
17 months. The primary endpoint was met – the addition of palbociclib to letrozole, as compared 
with placebo-letrozole, increased the median PFS from 14.5 months (95% confidence interval 
[CI], 12.9–17.1) to 24.8 months (95% CI, 22.1 to not estimable) (hazard ratio [HR] 0.58, 95% CI, 
0.46–0.72; p < 0.001). Subgroup analyses of PFS confirmed a consistent benefit across all sub-
groups evaluated including different race, prior disease-free survival, visceral involvement, prior 
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hormonal therapy, the type of recent hormonal therapy, or prior chemotherapy (HR ranges, 
0.35–0.67). The ORR for all randomly assigned patients in palbociclib-letrozole group versus pla-
cebo-letrozole group was 42.1% (95% CI, 37.5–46.9) and 34.7% (95% CI, 28.4–41.3) (odds ratio 1.4, 
95% CI, 0.98–2.01; p = 0.06). CBR among all patients randomized was 84.9% (95% CI, 81.2–88.1) 
for palbociclib-letrozole group and 70.3% (95% CI, 63.8–76.2) for placebo-letrozole group (odds 
ratio 2.39 (95% CI, 1.58–3.59; p < 0.0010). The most frequent grade 3 and 4 adverse event (AE) in 
the palbociclib-letrozole group was neutropenia (66%), but febrile neutropenia occurred in 1.8% 
of patients only. Other common AE included fatigue (37%), nausea (35%), arthralgia (33%), alo-
pecia (33%) and diarrhea (26%) and all these were mild.
PALAMO-3 is another indication-defining phase 3 study of palbociclib [30]. Patients with 
HR+ve/HER2−ve HER2-negative MBC who had relapsed or progressed during prior endocrine 
therapy were randomized to receive fulvestrant with placebo or fulvestrant with palbociclib. 
A total of 521 patients were randomized. The median PFS was 9.2 and 3.8 months in the ful-
vestrant-palbociclib and fulvestrant-placebo groups respectively (95% CI, 2.5–5.5) (HR 0.42, 
95% CI, 0.32–0.56; p < 0.001). ORR was 10.4% with fulvestrant-palbociclib and 6.3% with ful-
vestrant-placebo, and the CBR was 34% with fulvestrant-palbociclib and 19% with fulvestrant-
placebo. In the fulvestrant-palbociclib group, grade 3 or 4 neutropenia was found in 62%. 
Other common AEs were fatigue (38%), nausea (29%), anemia (26%), and headache (21%).
The results of PALOMA-2 echo those of PALOMA-1 that led to FDA approval. PALOMA-1 
differs from PALOMA-2, besides being a phase 2 trial, in that it adopted a 1:1 randomization. 
There were also small differences in the subgroup analysis, such as inclusion of the newly 
diagnosed metastatic disease subgroup. Nevertheless, both studies showed significant sur-
vival benefit of palbociclib and similar toxicity profiles.
3.1.2. Ribociclib
Ribociclib is the second CDK 4/6 inhibitor received the U.S. FDA approval in March 2017. 
The first approval study was MONOLEESA-2 for first line setting. MONOLEESA-7, which is 
also a first line trial, had special interest in pre- and peri-menopausal women. The data also 
became available recently.
3.1.2.1. Key results of phase 3 MONOLEESA studies
MONOLEESA-2 is a double-blind, placebo-controlled, phase 3 study of ribociclib plus letro-
zole [31]. It mirrors PALOMA-2 for the target patient population. Patients were randomized 
1:1 to ribociclib-letrozole or placebo-letrozole. The study demonstrated that the addition of 
ribociclib to letrozole significantly improved PFS from 14.5 months to over 25 months giving a 
HR of 0.56 for disease progression or death (95% CI, 0.43–0.72; p < 0.001). The ORR was 40.7% 
in the ribociclib group and 27.5% in the placebo group in the intention-to-treat population. 
The CBR was 79.6% in the ribociclib group and 72.8% in the placebo group (p = 0.02) respec-
tively in the intention-to-treat population. The most common grade 3 and 4 AEs were neu-
tropenia (60%), elevated alanine aminotransferase (9%), elevated aspartate aminotransferase 
(6%), infection (4%) and vomiting (4%). Other common AEs were minor and mild.
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The results of MONOLEESA-7 was first released in the San Antonio Breast Cancer Symposium 
(SABCS) 2017 [32]. Unlike other studies of CDK4/6 inhibitors, this study recruited pre- or 
perimenopausal HR+ve/HER2−ve MBC patients who had received no prior endocrine therapy 
for advanced disease, but allowed up to 1 line of chemotherapy. Patients were randomized to 
receive standard treatment of goserelin, plus either tamoxifen or AI, together with ribociclib 
or placebo. The median age of recruited patients were 44 years old, and 40% had de novo meta-
static disease. For those who developed metastasis after primary resection, more than 50% 
had disease-free interval for more than 12 months. Median PFS turned out to be 13.0 months 
for the placebo group and 23.8 months for the ribociclib group (HR 0.553; 95% CI, 0.441–0.694; 
p < 0.001). About ¼ of the patients received tamoxifen, and there was no difference from those 
who received AI in term of PFS benefit gained with addition of ribociclib. Goserelin was an 
effective method for ovarian suppression for treatment of pre/peri-menopausal HR+ve/HER2−ve 
MBC, and tamoxifen was as good as AI partnering with ribociclib.
3.1.3. Abemaciclib
In September 2017, abemaciclib was approved by the U.S. FDA to be used in combination 
with fulvestrant for HR-positive MBC progressed following endocrine therapy. It was also 
approved as monotherapy for HR-positive MBC with disease progression following endo-
crine therapy and chemotherapy in the metastatic setting.
3.1.3.1. Important clinical trials of abemaciclib
MONARCH-2 is a randomized placebo-controlled trial to study the combination of abemaci-
clib with fulvestrant in patients with HR+ve/HER2−ve MBC who have progressed on or had 
less than 12 months from end of adjuvant endocrine therapy [33]. Patient received abemaci-
clib daily without resting period. The original study dose was 200 mg BD, but the protocol 
amended to reduce the dose to 150 mg BD as there were many clinically significant diarrheas. 
Abemaciclib plus fulvestrant significantly prolonged median PFS versus fulvestrant alone 
(16.4 versus 9.3 months; HR 0.553; 95% CI, 0.449–0.681; p < 0.001). In the intention-to-treat 
population, abemaciclib plus fulvestrant achieved an ORR of 35.2% compared with 16.1% in 
the control arm (p < 0.001), and it included 14 patients with complete response (3.1%). The 
treatment gave durable response with 12-month duration of response rate of 67.8 and 66.9% 
in the abemaciclib and the placebo arm respectively. After 12 cycles of treatment, the mean 
change in tumor size for the abemaciclib arm and placebo arm were − 62.5% and − 32.8% 
respectively. The most common adverse events in the abemaciclib arm were diarrhea (all 
grade 86.4%, grade 3 & 4 13.4%), neutropenia (all grade 46.0%, grade 3 & 4 26.5%), nausea (all 
grade 45.1%, grade 3 2.7%), and fatigue (all grade 39.9%, grade 3 2.7%).
The results of MONARCH-3 came after MONARCH-2. MONARCH-3 is a double-blind ran-
domized phase 3 study of abemaciclib or placebo plus a non-steroid AI in HR+ve/HER2−ve 
MBC patients who had no prior systemic therapy in the advanced setting [34]. Patients were 
randomized to receive either abemaciclib 150 mg BD continuously or placebo with anastro-
zole 1 mg or letrozole 2.5 mg daily. Median PFS was significantly longer in the abemaciclib 
arm compared with placebo arm (HR 0.54; 95% CI, 0.41–0.72; p < 0.001). The ORR in the 
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intention-to-treat population was 48.2% and 34.5% for abemaciclib and placebo arms respec-
tively (p = 0.002). Diarrhea was reported in 81.3% but most was grade 1. The most common 
grade 3 or 4 toxicity was neutropenia (21.1%) and diarrhea (9.5%).
While most clinical trials of palbociclib and ribociclib focused on first or early line treatment 
for metastatic disease, abemaciclib is the only CDK4/6 inhibitor that has proven to have mean-
ingful activity in refractory disease. MONARCH-1 is a phase II single-arm open-label study 
for HR+ve/HER2−ve MBC patients who had progressed on or after endocrine therapy, and had 
1 or 2 chemotherapy regimens [35]. Abemaciclib was given at 200 mg BD continuously as 
monotherapy. The primary objective was ORR. Other endpoints included CBR, PFS, and 
OS. This study recruited 132 patients. Median line of treatment was 3. ORR was 19.7%, CBR 
was 42.4%, median PFS was 6.0 months, and median OS was 17.7 months. Major treatment-
related AEs were diarrhea (all grade 90.2%, grade 3 & 4 19.7%), fatigue (all grade 65.2%, grade 
3 12.9%), and nausea (all grade 64.4%, grade 3 4.5%). Neutropenia was reported in 87.5% of 
patients of which 26.9% were grade 3 or 4.
3.1.4. Biomarker of response
At the age of precision medicine, we aim to understand the potential biomarker of response 
that can guide us on treatment. For palbociclib, investigated biomarkers include cyclin D1 
amplification and p16 loss, ER expression, Rb level, and Ki67 index [28, 36], as well as hor-
mone-receptor expression level, PIK3CA mutation status, and plasma circulating tumor DNA 
ESR1 mutation status [37, 38]. No biomarker of response has been identified for palbociclib.
As to ribociclib, ctDNA was collected for MONALEESA-2 study at baseline. Although patient 
with PIK3CA variants had shorted PFS compared with those with wild-type PIK3CA, they 
derived similar PFS benefit to the addition of ribociclib (Altered PIK3CA HR 0.53, wild-type 
PIK3CA HR 0.44) [31]. Similarly, altered TP53 was a poor prognostic factor, yet both wild-type 
TP53 and altered TP53 had similar response to added benefit of ribociclib. There was a week 
trend toward limited PFS benefit with ribociclib was observed in patients with alteration in 
CDH1 and FGFR1/ZNF7–3. The incidence of these genetic events was found in only 5–11% 
of patients, thus the results still inconclusive. A better understanding in biology of endocrine 
resistance and obtaining study biopsy at the time of starting treatment or upon disease recur-
rence or progression might provide valuable insight in this field.
3.1.5. Discussion for CDK4/6 inhibitor
PALOMA-2 showed superior efficacy of adding palbociclib to letrozole in first line treatment 
of HR+ve/HER2−ve MBC with an unprecedented PFS of over 2 years. This benefit extended to all 
subgroups, including those with prior exposure to hormonal therapy or chemotherapy. This 
study confirms the new standard of adding CDK4/6 inhibitor in this disease.
The most concerning toxicity of palbociclib and ribociclib was neutropenia. It happened 
in 80–90% of patients of which grade 3 or 4 neutropenia was reported in 60%. Patients 
who developed neutropenic fever, grade 4 neutropenia, or prolonged neutropenia would 
require dose reduction. The significance of dose reduction is not clear. PALOMA-3 is a 
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study of palbociclib in combination with fulvestrant in patients who progressed on first 
line hormonal therapy [30]. Detailed analysis showed that dose modification of palbociclib 
for grade 3 and 4 neutropenia had no adverse effect on PFS [39]. Together with improved 
quality of life (QoL), and low incidence of neutropenic fever of less than 2%, palbociclib and 
ribociclib are drugs very well tolerated.
While PALOMA-1, PALOMA-2, and MONALEESA-2 provided the evidence to the use of 
CDK4/6 inhibitor in the first line setting, all these trials were done in post-menopausal women. 
In fact the last randomized trial dedicated to premenopausal women with MBS was pub-
lished almost 2 decades ago. It is estimated that around 1/5 of newly diagnosed breast cancer 
in the U.S. was found in women younger than 50 years old [40]. In Asia-Pacific region, 40% 
of breast cancer patients were of age less than 50 years [41]. Breast cancer in young patients 
is believe to be more aggressive and has distinct tumor biology. MONALEESA-7 is the first 
of the series to explore the activity of CDK 4/6 inhibitor in these patients. It extended the use 
of CDK4/6 inhibitor in pre/peri-menopausal women in combination with GHRH agonist as 
the mean of ovarian suppression. It also proved that tamoxifen was an as effective hormonal 
partner as AI with CDK4/6 inhibitor.
The hazard ratios for all first line trials of CDK4/6 inhibitor were similar, ranging between 
0.49 and 0.58. It appeared that these drugs had comparable efficacy. The choice of drug would 
probably depend on their toxicity profile, dosing regimen, or dosage form. The 3 CDK4/6 
inhibitors were not made equal. Palbociclib and ribociclib are structurally similar, basing off 
a pyrido [2,3-d]pyrimidin-7-one scaffold that was optimized for selectivity toward CDK4/6 
[42, 43]. Abemaciclib, on the other hand, derived from a 2-anilino-2,4-pyrimidine-[5-benz-
imidazole] scaffold. This compound not only has potent activity against CDK4 and 6, it also 
inhibits multiple kinases in vitro a concentration less than 100 nM [44]. Neutropenia is the 
most common side effect of palbociclib and ribociclib. It appeared that anemia, thrombocyto-
penia and possibly stomatitis were more common in patients given palbociclib. For ribociclib, 
results from MONOSEESA-2 showed grade 3 or 4 elevated alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST) in up to 9% of the patients. Prolonged QTcF was also 
a concern for a small proportion of patients in the study. Although palbociclib and riboci-
clib have comparable spectrum of CDK activity [45], the small disparities in their chemical 
structure might explain the differences in their toxicities. Abemaciclib, being structurally dis-
tinct from the other 2 CDK4/6 inhibitors, has diarrhea being the most reported adverse event. 
Grade 3 and 4 neutropenia was at around 21–25%, half of that reported in the PALOMA or 
MONALEESA trials. Due to the lower incidence of bone marrow toxicity, this drug is taken 
twice per day continuously without the need for a resting week. It is also the only CDK4/6 
inhibitor with an indication in heavily pretreated patients as a monotherapy.
Although HR+ve/HER2−ve breast cancer is regarded as a less aggressive form of breast cancer, 
a significant proportion of patients after curative resection ultimately relapse. The impres-
sive response in metastatic setting and decent QoL data of palbociclib suggest that this drug 
might have a role as adjuvant therapy and help prevent recurrence. A number of adjuvant 
trials are ongoing. For instance, PALLAS evaluates the outcome of adding 2 years of palboci-
clib to standard endocrine therapy [NCT02513394]. PENELOPE-B studies the role of adding 
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palbociclib to standard endocrine therapy in patients with high risk of relapse after neoadju-
vant chemotherapy [NCT01864746]. MonarchE [NCT03155997] is also recruiting. It studied 
the effect of adding 2 years of abemaciclib to standard adjuvant endocrine therapy in high-
risk node-positive early stage patients post-resection.
CDK4/6 inhibitors revolutionized how HR+ve/HER2−ve MBC should be treated. There is an 
unmet need for biomarker of response to guide management decision. Further studies on the 
benefit of continuing CDK 4/6 inhibitors beyond progression or the optimal time to add these 
targeted agents would also be needed.
3.2. Traditional mTOR inhibitor remains a standard treatment
mTOR is a downstream effector of the PI3K/AKT pathway. Targeting mTOR is a rational strat-
egy to reverse endocrine resistance. TAMRAD is a phase 2 study that explored the combination 
of oral mTOR inhibitor everolimus with tamoxifen versus tamoxifen in patients with HR+ve/
HER2−ve MBC who have progressed on AI [46]. The dosage of everolimus was 10 mg daily. This 
primary end point was CBR. Everolimus significantly improved the CBR from 42–61%. Time 
to progression increased from 4.5 months with tamoxifen alone to 8.6 months with addition of 
everolimus (HR 0.54; 95% CI, 0.36–0.81). Significant adverse reaction included fatigue (72%), 
stomatitis (56%), rash (44%), anorexia (43%), and diarrhea (39%). Second line AI is a common 
strategy upon progression on first line AI. BOLERO-2 is a phase 3 trial which randomized 
patients who have receive exemestane plus everolimus or everolimus alone [47]. Patients had 
recurrence or progression while on previous endocrine therapy with a nonsteroidal AI in 
the adjuvant setting or to treat advance disease. The primary end point was PFS. The study 
stopped early after the interim analysis, as median PFS was 6.9 months with everolimus plus 
exemestane, versus 2.8 months with exemestane alone (HR 0.43; 95% CI, 0.35–0.54; p < 0.001) 
based on assessments by local investigators. These patients were heavily pretreated – besides 
nonsteroidal AI, 57% had received an antiestrogen, 26% had chemotherapy in the advance 
setting, and 54% had 3 or more lines of therapies. Stomatitis was the most frequent and debili-
tating adverse events (all grades 56%, grade 3 8%), followed by rash (add grades 36%, grade 
3 1%), fatigue (all grades 33%, grade 3 3%), and diarrhea (all grades 30%, grade 3 2%). As 
everolimus is an immunosuppressant, the incidence of infection cannot be under-estimated 
and there were 2 cases of deaths from sepsis. Other class-specific severe toxicities included 
anemia (grade 3 5%), hyperglycemia (grade 3 4%), pneumonitis (grade 3 3%), and elevated 
AST (grade 3 3%) and elevated ALT (grade 3 3%). The study was not powered to detect a differ-
ence in OS, and the analysis of OS was negative [48]. Subsequent molecular analysis of archi-
val tissue showed that the mutational status of PIK3A, amplification of FGFR1, or P3K/AKT/
mTOR pathway alteration did not affect treatment response to everolimus [49]. This analysis 
reviewed some potential quantitative differences in the efficacy of everolimus among tumors 
of specific PIK3CA exons, FGFR2, mTOR, and chromosomal instabilities. These remains to be 
further investigated. BOLERO-2 also included analysis of plasma cell-free DNA (cfDNA) for 
2 ESR1 mutations [50]. ESR1 D538G mutation was detected in 21% and ESR1 Y537S mutation 
was found in 13%. Interestingly, patients with D538G mutation had PFS benefit with addition 
of everolimus (HR 0.34; 95 CI, 0.02–0.57), while those carrying Y537S mutation did not.
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Everolimus is an inhibitor of mTORC1. It is postulated that mTORC1 inhibition by everolimus 
set off negative feedback mechanism via AKT signaling, and leads to treatment resistance. 
Vistusertib is a small molecule ATP competitive dual inhibitor of mTORC1 and mTORC2. 
Preclinical model demonstrated that vistusertib had superior activity to everolimus in sup-
pressing tumor growth [51]. MANTA is a randomized phase 2 study of fulvestrant in combi-
nation with vistusertib or everolimus or fulvestrant alone in HR-positive HER2-negative MBC 
patients who have disease resistance to AI [52]. No more than 1 line prior chemotherapy was 
allowed in advanced setting. Primary end point was PFS. At median follow up of 17 months, it 
showed that addition of vistusertib did not add PFS benefit compared with fulvestrant alone 
(7.6 versus 5.4 months; HR 0.88; 95% CI, 0.63–1.24, p = 0.46). In fact, the fulvestrant-everolimus 
arm had superior PFS compared with the fulvestrant-vistusertib arm (12.3 versus 7.6 months; 
HR 0.63; 95% CI, 0.45–0.9, p = 0.01). Stomatitis and rash were the most common adverse effects 
of this dual mTOR inhibitor, and the frequency was comparable to that of everolimus. In sum-
mary, dual inhibition of mTOR did not derive superior effect. Everolimus remains the only 
mTOR inhibitor approved by the U.S. FDA for HR+ve/HER2−ve MBC.
3.3. PI3K inhibitors as an emerging treatment
Intracellular signaling pathways have complex interaction. Targeted inhibition of a particular 
component in the pathway might cause relief of upstream feedback inhibition. Inhibition of the 
effector mTOR in the PI3K/AKT/mTOR pathway, could result in adaptive hyperactivation of 
the upstream AKT activity and leads to treatment failure [53]. As PIK3CA mutation is the most 
common genetic changes in breast cancer and represents a more proximal target, targeting 
PIK3CA might exert upstream halt of growth signaling. A number of PI3K inhibitors have been 
developed. Pictilisib is an orally active pan-inhibitor of class 1 PIK3K. FERGI is a randomized 
phase 2 study which recruited HR+ve/HER2−ve MBC patients who have progressed on or after AI 
[54]. Patients were given either fulvestrant or fulvestrant with pictilisib. The primary end point 
was PFS. There was no difference between 2 groups, both in the intention-to-treat population 
or patients with PIK3CA mutation. Pictilisib-associated serious adverse events in the original 
study dose of 340 mg per day were reported in 16%, whereas those leading to discontinuation 
were rash, pneumonitis, diarrhea, abdominal pain, stomatitis or elevated AST or ALT. Close 
to half the patients required dose modification. Toxicities greatly limited drug exposure of the 
patients. Although in the second part of the study dosage has been reduced and toxicity profile 
improved, the drug was not further developed due to its lack of PFS benefit.
Another extensively studied PI3K inhibitor is buparlisib. It is also a pan-class I PI3K inhib-
itor. It showed encouraging results in early clinical studies and it was ultimately brought 
to a number of phase 3 trials. BELLL-2 combined fulvestrant with buparlisib or placebo in 
HR+ve/HER2−ve MBC patients who have progressed on or after AI, and had received up to 1 
line of chemotherapy in the advanced setting [55]. The median PFS was 6.9 months in the 
buparlisib group versus 5.0 months in the placebo group (HR 0.78; 95% CI, 0.67–0.l89; one 
sided p < 0.001). In patients with PI3K pathway-activation, median PFS was 6.8 months in the 
buparlisib group versus 4.0 months in the placebo group (HR 0.76; one sided PFS p −0.014). 
The most common grade 3 or 4 toxicities in the buparlisib group was increased ALT (25%), 
increased AST (18%), hyperglycemia (15%), and rash (8%). As preclinical data showed that 
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buparlisib in combination with fulvestrant can reverse resistance mTOR inhibitor (Novartis 
data), BELLE-3 studied the combination of fulvestrant with or without buparlisib in HR+ve/
HER2−ve MBC patients who have progressed on or after mTOR inhibition [56]. It demonstrated 
that addition of buparlisib to fulvestrant prolonged the median PFS 1.8 months to 3.9 months 
(HR 0.67; 95% CI, 0.53–0.84, one-sided p < 0001). Circulating tumor DNA (ctDNA) analysis of 
PIK3CA status was available. Of the 432 subjects, 34% carried PIK3CA mutation. Among these 
patients, the median PFS was 4.7 months for those in the buparlisib arm versus 1.6 months 
for those in the placebo arm, thus those who received the PI3K inhibitor were 50% less likely 
to have disease progression. Despite these encouraging findings, grade 3 or 4 adverse events 
related to buparlisib were alarming – they included elevated ALT (22%), elevated AST (18%), 
and hyperglycemia (12%). Other toxicities potentially related to the drug such as depression, 
anxiety, and rash were also concerning. The company decided not to pursue further develop-
ment of the drug due to its safety profile.
On the other hand, the company has turned its focus to a α-specific PI3K inhibitor alpelisib. 
Early phase study showed preliminary preferential antitumor activity in PIK3CA-altered 
tumor treated with alpelisib [57]. A presentation of the preliminary results for the combination 
of alpelisib and fulvestrant demonstrated encouraging early efficacy [58]. The study recruited 
87 patients with HR+ve/HER2−ve MBC. Alpelisib was given at 300 mg on a continuous daily 
schedule. In the PIK3A-altered population, the CBR was 45%. Median PFS was 9 and 5 months 
in the PIK3CA-altered groups and PIK3CA wild-type group respectively. This drug appeared 
to be better tolerated than pan-PI3K inhibitors. At the moment, the phase III SOLAR-1 trial 
[NCT02437318] studying the same combination in patients who have progressed on or have 
failed AI is ongoing. First PFS analysis is expected to be available later the year.
3.4. SERDS and its new role
Fulvestrant is the only clinically available SERD. It targets the ER for proteasomal degradation 
and halts the action of estrogen. It is capable of binding to the ligand-binding domain of ERα, 
converting it to a form incapable with transcriptional activity [59, 60]. Fulvestrant is given by 
intramuscular injection on day 1, 15, 29, then every 28 days. The initial studied and market 
dose was 250 mg. At first line setting, as in the FACT study (SWOG S0226 trial), fulvestrant 
at 250 mg did not demonstrate survival advantage over AI [61]. As second line treatment, 
fulvestrant at 250 mg showed similar time to progression (TTP) to anastrozole. Yet the later 
CONFIRM study demonstrated that doubling the dose to 500 mg gave a superior PFS and OS 
compared with 250 mg [5, 62]. FALCON is a phase 3 study which further brings fulvestrant at 
500 mg to first line setting in comparison with anastrozole. The PFS was 16.6 and 13.8 months 
for the fulvestrant and anastrozole groups respectively with a p value of 0.0486 [6].
Given the special property of SERD on receptor degradation and conformation, it would be 
interesting to explore if patients with ESR1 mutation respond differently from those with 
ESR1 wild type. SoFEA is a study comparing exemestane with fulvestrant-containing regi-
mens in patients with prior sensitivity to nonsteroidal AI. Prospective-retrospective analysis 
of plasma ctDNA from SoFEA found ESR1 mutation in 39% of patients, of which half were 
polyclonal [63]. Those with ESR1 mutation had better PFS after giving fulvestrant compared 
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with exemestane (HR 0.52, p = 0.02). Patients with ESR1 wild type had similar benefit given 
either drug. PALOMA3 is a study that compared fulvestrant plus placebo with fulvestrant 
plus palbociclib in patients with progression after prior endocrine therapy. Plasma ctDNA 
analysis showed ESR1 mutation rate of 25%, of which 28% where polyclonal. Fulvestrant plus 
palbociclib gave rise to better PFS compared with fulvestrant alone in both ESR1 mutant (HR 
0.43, p = 0.002) and ESR1 wild type patients (0.49, p < 0.001) [63]. Analysis of ctDNA from the 
BOLERO2 study also supported that ESR1 mutation can be found in around 30% of patients 
who have failed prior endocrine therapy [50]. Patients with ESR1 mutation had shorted OS 
compared with wild type. This study did not involve the use of fulvestrant.
While fulvestrant is non-inferior to AI in the first line setting, more data on OS is awaited. 
Yet emerging evidence suggest that testing of ESR1 mutation could probably guide us in 
the choice of hormonal therapy in patients who have failed prior endocrine therapy. The 
approach is limited by the availability of ctDNA analysis, sensitivity of different ctDNA meth-
odology, often difficult-to-obtain tissue biopsy upon the time of progression, and accessibility 
to ESR1 test in local laboratory as it is still not a standard practice.
4. The sequence of endocrine therapy and targeted drugs
AI has been the standard of care for first line treatment of patients with HR+ve/HER2−ve MBC. The 
role of fulvestrant has been controversial. Due to the high cost, the need for monthly injection, 
and similar efficacy in the first line setting, fulvestrant is often an option rather than the pre-
ferred choice. Yet much remained to be learnt from this SERD. In the phase 3 FALCON trial, 
patients given monthly injection of fulvestrant at 500 mg had borderline statistically longer 
median PFS of 16.6 months (95% CI, 13.83–20.99) compared with those of 13.8 months (95% 
CI, 11.99–16.59) given oral anastrozole 1 mg daily (HR 0.797, 95% CI, 0.637–0.999; p = 0.0486) 
[6]. This approach showed that the ceiling PFS ceiling of hormonal therapy could be stretched 
to 20 months in some patients. More interestingly, subgroup analysis suggested that most of 
the survival benefit was derived from patients who had bone-only metastatic disease, with a 
median PFS of 22.3 month in the fulvestrant group versus 13.8 months in the anastrozole group 
(HR 0.59; 95 CI, 042–0.84). Reanalysis of SOG S0226 according to prior exposure to adjuvant 
adjuvant tamoxifen, showed that those without prior endocrine exposure had longer median 
PFS when given fulvestrant compared with anastrozole (16.7 versus 12.7 months; HR 0.73; 
95% CI, 0.60–0.89, p = 0.002), which further translated into improved median OS by 1 year 
(40.3 versus 52.2 months, p = 0.0067) [64]. With the emergence of new treatment option of mul-
tiple CDK4/6 inhibitors, and the increasing financial burden associated with them, the practical 
questions would be how to choose the first line hormonal therapy. There have been interna-
tional guidelines to lay the general clinical principle that treatment recommendation should 
be based on if the patient is naïve to endocrine therapy, the type of adjuvant therapy, length of 
disease free interval and if disease relapsing less than 12 months from the end of adjuvant AI 
[65, 66]. More updated and detailed guidelines are anticipated in light of new findings.
As to the choice of agent in the second line setting or beyond, the choice would largely depend 
on prior treatment. Some general principles are becoming apparent. First of all, there is 
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enough data to suggest that CDK4/6 inhibitor should be part of standard treatment in patients 
with HR+ve/HER2−ve MBC, be it first line (PALOMA-2, MONALEESA-2, MONARCH-3, 
MONALEESA-7), second line (PALOMA-3, MONARCH-2), or later line in refractory cases 
(MONARCH-1). Since PI3K/AKT/mTOR plays an important role in hormonal resistance, 
mTOR inhibitor should also be considered in all patients. The only approved choice cur-
rently is everolimus. For the choice of hormonal partner in patients who have progressed 
on or failed prior AI, testing of ESR1 mutation status might provide some guidance as to if 
switching to SERD would be helpful. It is still not clear if patients who progress on first line 
CDK4/6 inhibitors should be continued this targeted agent with a switch of hormonal partner. 
Chemotherapy should be reserved for patients who have exhausted the options for hormonal 
therapy and these targeted therapies, or patients with impending visceral crisis.
5. Conclusion
Although we are becoming increasingly equipped to overcome resistance to hormonal 
therapy, these treatment would fail nevertheless. The preliminary OS data for the phase II 
PALOMA-1 trial was presented in June 2017. It showed that the median OS was 37.5 months 
in patients who received palbociclib and AI versus 34.5 months in those who received AI 
(HR 0.897) [67], suggesting the impressive gain in median PFS after adding palbociclib might 
not translate into long term survival. Interestingly, analysis of OS for BELL2 appears to be 
trending toward similar observation. The median OS for patients who received buparlisib 
and fulvestrant versus those who received placebo and fulvestrant was 33.2 and 30.4 months 
respectively (HR 0.87; 95% CI, 0.74 to 1.02; p = 0.045) [68]. Even in patients who had PI3K path-
way activated or PIK3CA mutation, the improvement in median PFS with addition of bupar-
lisib did not translate into better median OS (HR 0.81, p > 0.05). These might be explained by 
two reasons. Firstly, post-progression survival can be affected by availability and effective-
ness of subsequent therapy. Second, progression on CDK4/6 inhibitor might have selected 
out patients who then became refractory to other treatment especially chemotherapy. More 
understanding in the mechanism of resistance to hormonal therapy and targeted therapy is 
needed to overcome these barriers.
HR+ve/HER2−ve MBC is the most common type of breast cancer. The main stay of treatment is 
hormonal therapy, and the choice of hormonal therapy includes SERM, AI, and SERD. SERD 
might play a more important role in selected patients, as development of ESR1 mutation 
could render patients resistant to AI. Addition of targeted therapy such as CDK4/6 inhibi-
tor or mTOR inhibitor can help prolong the use of hormonal therapy, and should be part of 
standard treatment for all patients in their treatment journey. Future research would focus on 
strategies to overcome resistance to these therapies.
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